CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 9 target
Drug / intervention
Low Dose PD-1 mRNA LNP Vaccine +1 moredrug
Likely dose
Low Dose PD-1 mRNA LNP Vaccine 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07053072
NCT07053072Phase 1RecruitingOn TrackUpdated 2mo ago
CompareCT.gov

A Prospective，Single Arm Clinicial Trial Evaluating PD-1 mRNA LNP Vaccine for the Treatment of Advanced Primary Hepatocellular Carcinoma Failing Standard Therapy

West China Hospital·interventional·Posted Jul 8, 2025·Updated Apr 23, 2026

In Brief

A Phase 1 clinical trial evaluating Low Dose PD-1 mRNA LNP Vaccine and High dose PD-1 mRNA LNP vaccines for Liver Cancer. Currently recruiting, targeting 9 participants across 2 sites.

Detailed Summary

Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20262027
First PostedJul 8, 2025
Enrollment StartOct 23, 2025
Primary CompletionSep 30, 2026
Study CompletionDec 30, 2026
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 12 months agoPrimary completion in 3 months

Interventions

Low Dose PD-1 mRNA LNP Vaccinedrug

Patients will receive PD-1 mRNA LNP vaccine at 50 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.

High dose PD-1 mRNA LNP vaccinesdrug

Patients will receive PD-1 mRNA LNP vaccine at 100 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.